Literature DB >> 16950171

Effect of impaired myocardial reperfusion on left ventricular remodeling in patients with anterior wall acute myocardial infarction treated with primary coronary intervention.

Aleksander Araszkiewicz1, Stefan Grajek, Maciej Lesiak, Marek Prech, Małgorzata Pyda, Magdalena Janus, Andrzej Cieslinski.   

Abstract

We assessed the effect of impaired myocardial blush after primary coronary intervention (PCI) on left ventricular remodeling in patients with ST-segment elevation myocardial infarction (STEMI). The study population consisted of 145 patients with first anterior STEMI that was treated successfully (Thrombolysis In Myocardial Infarction grade 3 flow) with PCI. Left ventricular remodeling was defined as an increase of > or =20% in end-diastolic volume based on repeated echocardiographic measurements in patients. The study population was divided into 2 groups according to the presence (myocardial blush grade [MBG] 2 to 3, n = 86) or absence (MBG 0 to 1, n = 59) of myocardial reperfusion. Left ventricular remodeling appeared in 21% of the entire study group. Poor myocardial blush after PCI was associated with an increased rate of remodeling compared with good myocardial reperfusion (32% vs 14%, hazard ratio 2.308, 95% confidence interval [CI] 1.21 to 4.39, p=0.014). Symptoms of heart failure were observed significantly more often in patients with MBG 0 to 1 (35.6% vs 18.6%, p = 0.032) than in patients with MBG 2 to 3. In multivariate analysis, only age (odds ratio 0.96, 95% CI 0.92 to 0.99, p = 0.02) and MBG 0 to 1 (odds ratio 3.15, 95% CI 1.35 to 7.31, p = 0.008) were associated with left ventricular dilation. In conclusion, impaired microvascular reperfusion is associated with left ventricular remodeling and development of congestive heart failure in patients with anterior STEMI that is treated with primary coronary angioplasty.

Entities:  

Mesh:

Year:  2006        PMID: 16950171     DOI: 10.1016/j.amjcard.2006.04.009

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  15 in total

1.  Injectable shear-thinning hydrogels used to deliver endothelial progenitor cells, enhance cell engraftment, and improve ischemic myocardium.

Authors:  Ann C Gaffey; Minna H Chen; Chantel M Venkataraman; Alen Trubelja; Christopher B Rodell; Patrick V Dinh; George Hung; John W MacArthur; Renganaden V Soopan; Jason A Burdick; Pavan Atluri
Journal:  J Thorac Cardiovasc Surg       Date:  2015-07-17       Impact factor: 5.209

2.  Tissue-engineered, hydrogel-based endothelial progenitor cell therapy robustly revascularizes ischemic myocardium and preserves ventricular function.

Authors:  Pavan Atluri; Jordan S Miller; Robert J Emery; George Hung; Alen Trubelja; Jeffrey E Cohen; Kelsey Lloyd; Jason Han; Ann C Gaffey; John W MacArthur; Christopher S Chen; Y Joseph Woo
Journal:  J Thorac Cardiovasc Surg       Date:  2014-06-28       Impact factor: 5.209

3.  Computational protein design to reengineer stromal cell-derived factor-1α generates an effective and translatable angiogenic polypeptide analog.

Authors:  William Hiesinger; Jose Manuel Perez-Aguilar; Pavan Atluri; Nicole A Marotta; John R Frederick; J Raymond Fitzpatrick; Ryan C McCormick; Jeffrey R Muenzer; Elaine C Yang; Rebecca D Levit; Li-Jun Yuan; John W Macarthur; Jeffery G Saven; Y Joseph Woo
Journal:  Circulation       Date:  2011-09-13       Impact factor: 29.690

Review 4.  Diastolic ventricular support with cardiac support devices: an alternative approach to prevent adverse ventricular remodeling.

Authors:  Pavan Atluri; Michael A Acker
Journal:  Heart Fail Rev       Date:  2013-01       Impact factor: 4.214

Review 5.  Re-engineered stromal cell-derived factor-1α and the future of translatable angiogenic polypeptide design.

Authors:  William Hiesinger; Andrew B Goldstone; Y Joseph Woo
Journal:  Trends Cardiovasc Med       Date:  2012-08-16       Impact factor: 6.677

6.  Preclinical evaluation of the engineered stem cell chemokine stromal cell-derived factor 1α analog in a translational ovine myocardial infarction model.

Authors:  John W Macarthur; Jeffrey E Cohen; Jeremy R McGarvey; Yasuhiro Shudo; Jay B Patel; Alen Trubelja; Alexander S Fairman; Bryan B Edwards; George Hung; William Hiesinger; Andrew B Goldstone; Pavan Atluri; Robert L Wilensky; James J Pilla; Joseph H Gorman; Robert C Gorman; Y Joseph Woo
Journal:  Circ Res       Date:  2013-12-23       Impact factor: 17.367

7.  Normalization of postinfarct biomechanics using a novel tissue-engineered angiogenic construct.

Authors:  Pavan Atluri; Alen Trubelja; Alexander S Fairman; Philip Hsiao; John W MacArthur; Jeffrey E Cohen; Yasuhiro Shudo; John R Frederick; Y Joseph Woo
Journal:  Circulation       Date:  2013-09-10       Impact factor: 29.690

8.  Sustained release of engineered stromal cell-derived factor 1-α from injectable hydrogels effectively recruits endothelial progenitor cells and preserves ventricular function after myocardial infarction.

Authors:  John W MacArthur; Brendan P Purcell; Yasuhiro Shudo; Jeffrey E Cohen; Alex Fairman; Alen Trubelja; Jay Patel; Philip Hsiao; Elaine Yang; Kelsey Lloyd; William Hiesinger; Pavan Atluri; Jason A Burdick; Y Joseph Woo
Journal:  Circulation       Date:  2013-09-10       Impact factor: 29.690

Review 9.  Engineered biomaterials for heart disease.

Authors:  Lyndsay Stapleton; Yuanjia Zhu; Yi-Ping Joseph Woo; Eric Appel
Journal:  Curr Opin Biotechnol       Date:  2020-10-01       Impact factor: 9.740

Review 10.  The Expanding Armamentarium of Innovative Bioengineered Strategies to Augment Cardiovascular Repair and Regeneration.

Authors:  Stefan Elde; Hanjay Wang; Y Joseph Woo
Journal:  Front Bioeng Biotechnol       Date:  2021-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.